

composition, in particular a solid pharmaceutical composition, in particular a capsule or a tablet.

5 In another aspect, there is provided use of meglumine in a pharmaceutical composition to increase the chemical stability of N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof, contained in said composition.

10 In another aspect, there is provided use of meglumine in a pharmaceutical composition to prevent, postpone, slow down or diminish the transformation of N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof, contained in the composition, into 6,8-dimethoxy-4-(1-methylethyl)-1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine, a pharmaceutically acceptable salt thereof or a solvate thereof.

15 In another aspect, there is provided a method of preventing, postponing, slowing down or diminishing the transformation of N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof, contained in a pharmaceutical composition, into 6,8-dimethoxy-4-(1-methylethyl)-1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine, a pharmaceutically acceptable salt thereof or a solvate thereof, comprising adding meglumine to said composition.

20 In another aspect, there is provided use of a pharmaceutical composition as defined herein for the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered daily for 3 weeks (3 weeks on), followed by 1 week wherein the composition is not administered (1 week off), and repeating this cycle of 3 weeks on, 1 week off.

25 In another aspect, there is provided use of a pharmaceutical composition as defined herein for the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered daily for 1 week (1 week on), followed by 1 week wherein the composition is not administered (1 week off), and repeating this cycle of 1 week on, 1 week off.

30 In another aspect, there is provided use of a pharmaceutical composition as defined herein for the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered daily.

35 In another aspect, there is provided use of a pharmaceutical composition as defined herein for the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered once daily.

CLAIMS

1. The use of meglumine in a pharmaceutical composition to increase the chemical
5 stability of N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof, contained in said composition.
2. The use of meglumine in a pharmaceutical composition to prevent, postpone, slow
10 down or diminish the transformation of N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof, contained in the composition, into 6,8-dimethoxy-4-(1-methylethyl)-1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine, a pharmaceutically
15 acceptable salt thereof or a solvate thereof.
3. The use according to claim 1 or 2, wherein the pharmaceutical composition is a tablet or a capsule.
- 20 4. The use according to any one of claims 1 to 3, wherein the pharmaceutical composition comprises N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine base.
5. A method of preventing, postponing, slowing down or diminishing the transformation
25 of N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof, contained in a pharmaceutical composition, into 6,8-dimethoxy-4-(1-methylethyl)-1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine, a pharmaceutically acceptable salt thereof or a solvate thereof,
30 comprising adding meglumine to said composition.

6. The method according to claim 5, wherein the pharmaceutical composition is a tablet or a capsule.
7. The method according to claim 5 or 6, wherein the composition comprises N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine base.
8. A pharmaceutical composition comprising N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof; meglumine; and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition according to claim 8 comprising from about 0.1 to about 3 % w/w of meglumine based on the pharmaceutical composition.
10. A pharmaceutical composition according to claim 8 or 9, wherein the composition is a tablet or a capsule.
11. A pharmaceutical composition according to any one of claims 8 to 10, wherein the composition comprises from 0-2 % w/w of 6,8-dimethoxy-4-(1-methylethyl)-1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine based on the pharmaceutical composition, a pharmaceutically acceptable salt thereof or a solvate thereof.
12. A pharmaceutical composition according to claim 11, wherein the composition comprise from 0-0.05 % w/w of 6,8-dimethoxy-4-(1-methylethyl)-1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine based on the pharmaceutical composition, a pharmaceutically acceptable salt thereof or a solvate thereof.
13. A pharmaceutical composition according to any one of claims 8 to 12 comprising from 2 mg to 6 mg base equivalent of N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, a pharmaceutically acceptable salt thereof or a solvate thereof.

14. A pharmaceutical composition according to any one of claims 8 to 13, wherein the composition comprises N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine base.

5 15. The use of a pharmaceutical composition according to any one of claims 8 to 14 for the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered daily for 3 weeks (3 weeks on), followed by 1 week wherein the composition is not administered (1 week off), and repeating this cycle of 3 weeks on, 1 week off.

10

16. The use of a pharmaceutical composition according to any one of claims 8 to 14 for the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered daily for 1 week (1 week on), followed by 1 week wherein the composition is not administered (1 week off), and repeating this cycle of 1 week on, 1 week off.

15

17. The use of a pharmaceutical composition according to any one of claims 8 to 14 for the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered daily.

20

18. The use of a pharmaceutical composition according to any one of claims 8 to 14 for the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered once daily.

25 19. The use of a pharmaceutical composition according to any one of claims 15 to 18, (i) for the manufacture of a medicament for the treatment of cancer, wherein the daily dose is 6 mg base equivalent;

- (ii) for the manufacture of a medicament for the treatment of cancer, wherein the daily dose is 7 mg base equivalent;
 - (iii) for the manufacture of a medicament for the treatment of cancer, wherein the daily
5 dose is 8 mg base equivalent; or
 - (iv) for the manufacture of a medicament for the treatment of cancer, wherein the daily dose is 9 mg base equivalent.
- 10 20. The use of a pharmaceutical composition according to any one of claims 15 to 19
- (i) for the manufacture of a medicament for the treatment of cancer, wherein the cancer is bladder cancer;
 - (ii) for the manufacture of a medicament for the treatment of cancer wherein the cancer
15 is urothelial cancer;
 - (iii) for the manufacture of a medicament for the treatment of cancer wherein the cancer is metastatic urothelial cancer;
 - (iv) for the manufacture of a medicament for the treatment of cancer wherein the cancer
20 is surgically unresectable urothelial cancer;
 - (v) for the manufacture of a medicament for the treatment of cancer wherein the cancer is cholangiocarcinoma; or
 - (vi) for the manufacture of a medicament for the treatment of cancer wherein the cancer
25 is non-muscle-invasive bladder cancer.
- 30 21. The use of a pharmaceutical composition according to claim 20 wherein the cancer is a cancer with FGFR genomic alterations.
22. The use of a pharmaceutical composition according to claim 21 wherein the FGFR genomic alterations are translocations, fusions and/or mutations.
- 35 23. The use of a pharmaceutical composition according to claim 22 wherein the alteration is a FGFR3-TACC3 translocation.

24. The use of a pharmaceutical composition according to claim 22 wherein the alteration is a mutation.

5 25. The use of a pharmaceutical composition according to claim 24 wherein the mutation is R248C.

26. The use of a pharmaceutical composition according to claim 24 wherein the mutation is S249C.

10 27. The use of a pharmaceutical composition according to any one of claims 15 to 19
(i) for the manufacture of a medicament for the treatment of cancer wherein the cancer is advanced or refractory non small cell lung cancer (NSCLC), breast cancer, glioblastoma multiforme, urothelial cancer, ovarian cancer, head and neck cancer, oesophageal cancer, gastric cancer and cholangiocarcinoma;

15 (ii) for the manufacture of a medicament for the treatment of cancer wherein the cancer is multiple myeloma, myeloproliferative disorders, endometrial cancer, prostate cancer, bladder cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, colorectal cancer, and oral squamous cell carcinoma; or

20 (iii) for the manufacture of a medicament for the treatment of cancer wherein the cancer is endometrial, ovarian, gastric, hepatocellular, uterine, cervix and colorectal cancer.